Osimertinib Recruiting Phase 2 Trials for Non-Small Cell Lung Cancer With EGFR T790M Mutation / With Brain and/or Leptomeningeal Metastasis / Failed Tyrosine Kinase Inhibitors Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03257124Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS